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Abstract
Purpose: To access the long-time outcome and patterns of failure in patients with advanced head and neck
squamous cell carcinoma (HNSCC).
Methods and materials: Between 1992 and 2005 127 patients (median age 55 years, UICC stage III n = 6, stage IV
n = 121) with primarily inoperable, advanced HNSCC were treated with definite platinum-based
radiochemotherapy (median dose 66.4 Gy). Analysed end-points were overall survival (OS), disease-free survival
(DFS), loco-regional progression-free survival (LPFS), development of distant metastases (DM), prognostic factors
and causes of death.
Results: The mean follow-up time was 34 months (range, 3-156 months), the 3-, 5- and 10-year OS rates were
39%, 28% and 14%, respectively. The median OS was 23 months. Forty-seven patients achieved a complete
remission and 78 patients a partial remission. The median LPFS was 17 months, the 3-, 5- and 10-year LPFS rates
were 41%, 33% and 30%, respectively. The LPFS was dependent on the nodal stage (p = 0.029). The median DFS
was 11 months (range, 2-156 months), the 3-, 5- and 10-year DFS rates were 30%, 24% and 22%, respectively.
Prognostic factors in univariate analyses were alcohol abuse (n = 102, p = 0.015), complete remission (n = 47, p <
0.001), local recurrence (n = 71, p < 0.001), development of DM (n = 45, p < 0.001; median OS 16 months) and
borderline significance in nodal stage N2 versus N3 (p = 0.06). Median OS was 26 months with lung metastases (n
= 17). Nodal stage was a predictive factor for the development of DM (p = 0.025). Cause of death was most
commonly tumor progression.
Conclusions: In stage IV HNSCC long-term survival is rare and DM is a significant predictor for mortality. If patients
developed DM, lung metastases had the most favourable prognosis, so intensified palliative treatment might be
justified in DM limited to the lungs.
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Introduction
The incidence of oropharyngeal cancer in German men
in 2004 was 16.3 per 100.000 [1]. Smoking and alcohol
consumption were known risk factors for the develop-
ment of head and neck squamous cell carcinoma
(HNSCC)[2,3]. New and optimized treatment methods
increase loco-regional progression-free survival (LPFS)
and disease-free survival (DFS) in patients with advanced
head and neck carcinomas and thereby overall survival
(OS) in the short-term follow-up [4-7]. Data on long-
term follow-up and patterns of failure are rare [8]. The
published incidence of distant metastases (DM) in
HNSCC is widespread and varies between 6% and 47%
[9-14]. Spector et al published e. g. an incidence of 8.5%
in 2550 patients treated for squamous cell carcinomas of
the larynx and hypopharynx between 1971 and 1991 [14].
The published incidence of DM in a subgroup of patients
with stage IV disease was even as high as 55%[15].
Reported factors influencing the incidence of DM were
tumor stage, especially the extension of nodal disease,
histological patterns and loco-regional tumor control
[9,16-18]. Lim et al reported that the presence of patho-
logic lymph nodes, especially bilateral neck metastases,
was an independent risk factor for the development of
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[16]. The leading site for DM were the lungs, followed by
the skeletal system [9,14]. So DM might become a rele-
vant problem and data on outcome is warranted to
improve the adaption of the treatment. This retrospective
study performs uni- and multivariate analyses on the out-
come of patients treated with concurrent platinum-based,
hyperfractionated-accelerated radiochemotherapy for pri-
marily inoperable, advanced HNSCC according to the
treatment protocol of Staar et al. [19]. Furthermore fac-
tors possibly impacting on the development of DM in
patients with advanced HNSCC were analyzed to identify
subgroups, in which additional diagnostic and/or thera-
peutically options might improve prognosis, morbidity
and mortality.
Patients and methods
Patient characteristics
From 1992 to 2005 127 patients (median age 55 years,
range 32-79 years; male n = 110, female n = 17) were
treated according to the treatment protocol of Staar et
al. [19] with a definite platinum-based concurrent
hyperfractionated-accelerated radiochemotherapy for
primarily inoperable, advanced oro- (n = 41) and hypo-
pharyngeal (n = 86) squamous cell carcinoma at the
Department of Radiation Oncology of the University
Hospital Heidelberg. Patients treated with other treat-
ment regimes for the same disease were excluded. All
patients were initially staged as free of DM. Further
patient characteristics are listed in table 1.
Diagnostic work-up and Treatment
The initial workup included physical and laboratory
examinations, imaging procedures, such as x-ray studies,
ultrasound (US), magnetic resonance imaging (MRI) or
computerized tomography scans (CT) as well as biop-
sies. Positron-emission tomography (PET) was not per-
formed on a regular base. Data on HPV16/p16 was
retrospectively accessible in 43 (34%) of the patients.
Five of these patients were HPV16/p16 positive. The
treatment consisted of a concurrent hyperfractionated-
accelerated radiotherapy and platinum-based che-
motherapy. Irradiation was planned using two- or three-
dimensional-based techniques and controlled by simula-
tor-based imaging. Patient immobilization was done by
thermoplastic masks. Megavolt radiotherapy was admi-
nistered by linear accelerators to a median dose of 66.4
Gy (range, 59.4-70.3 Gy). The median time interval
between initial diagnosis and first irradiation was 25
days. Chemotherapy consisted of 5-FU (600 mg/m
2
body surface) as a continuous infusion and carboplati-
num (70 mg/m
2 b o d ys u r f a c e )a ss h o r t - t e r mi n f u s i o n
day 1-5 and 29-33. Ten patients had to quit chemother-
apy early due to toxicity (n = 2), personal wish (n = 2)
or undocumented reasons (n = 6). Regular follow-up
examinations included clinical examination, US, MRI or
CT and were classified as complete remission (CR,
requiring no detectable disease), partial remission (PR,
tumor mass reduction of at least 50%), no response
(NR, less than 50% tumor mass reduction) or as pro-
gressive disease (PD). The first follow-up examination
was scheduled 6 to 8 weeks after radiotherapy was fin-
ished. Radiooncological treatment time ranged between
31 and 80 days (median 40 days).
Statistics
The tumor was staged according to the TNM classifica-
tion recommended by the International Union against
Cancer (UICC) 1997. The latter was analysed regarding
overall survival (OS), disease-free survival (DFS), loco-
regional progression-free survival (LPFS), distant metas-
tases-free survival (DMFS) and causes of death. Statisti-
cal analyses were carried out with SPSS statistical
package (SPSS Inc., Chicago, IL, U.S.A.) using log-rank
test (Mantel-Cox), Kaplan-Meier’s estimation, multivari-
ate Cox-regression analysis (backwards stepwise, p out
>0.1, factors included: total dose of irradiation (>/= or <
66,4Gy); treatment time (>/= or <40 days); alcohol
Table 1 Patient characteristics
Patient characteristic No. of
patients
Percentage
Gender
Male 110 87
Female 17 13
Tumor localization
Oropharyngeal 86 68
Hypopharyngeal 41 32
Etiologic factors
Alcohol abuse 102 80
Tobacco abuse 99 78
HPV16/p16
Positive 5 12
Negative 38 88
TNM-Staging
T2 9 7
T3 24 19
T4 94 74
Tx 3 2
N0 7 6
N1 6 5
N2 (a/b/c) 97 (2/35/60) 77 (2/28/
47)
N3 17 13
Tumor stage according to UICC
classification 1997
III IVA 6 104 5 82
IVB 17 13
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versus IVb; stage N2 versus N3; localization oro- versus
hypopharynx; CR versus PR; distant metastases; loco-
regional recurrence) and Fisher’s exact test. Significance
was defined as p-value < 0.05. All time estimates began
with the initiation of radiation treatment. Documented
long-term side effects were classified according to the
RTOG/EORTC Late Radiation Morbidity Scoring
Scheme (Appendix IV, CTC Version 2.0).
Results
Response to treatment and loco-regional control
The mean follow-up time was 34 months (range, 3-156
months). Forty-seven patients (37%; n = 29 hypopharyn-
geal- and n = 18 oropharyngeal carcinoma) achieved a
complete remission, whereas 78 patients (61%; n = 55
hypopharyngeal- and n = 23 oropharyngeal carcinoma)
showed a partial remission. One patient (1%) had pro-
gressive disease. No treatment response was available in
one patient (1%). The median LPFS was 17 months, the
3-, 5- and 10-year LPFS rates were 41%, 33% and 30%,
respectively. The median LPFS was significantly different
(p = 0.029) in patients with N0 disease (20 months), N1
disease (43 months), N2 disease (18 months) and N3
disease (7 months).
Distant metastases and distant metastases-free survival
Distant metastases-free survival was median 66 months
(range, 2-156 months). Forty-five of our patients (35%;
41 male and 4 female; mean age 55 years, range 37-79
years) were diagnosed with distant metastases in the
median 8 months after initial diagnosis. The nodal stage
in these 45 patients was distributed as follows: N0 n =
4, N1 n = 0, N2a/b n = 17, N2c n = 17, N3 n = 8. Diag-
nosis of DM was primarily based on imaging proce-
dures, such as x-ray studies and CT scans. The locations
of DM were most commonly the lungs (38%), followed
by multiple locations (36%), the skeletal system (11%),
liver (9%), brain (4%) and skin (2%). Palliative treatment
regimes most commonly included different systemic
therapies, in localized DM additionally palliative irradia-
tion or stereotactic radiotherapy but also surgical proce-
dures like metastasectomy. The development of DM led
to a significantly shorter median OS time compared to
38 months without DM (p < 0.001). The median OS in
the 45 patients with DM was 15.6 months (figure 1,
range 3-126 months) and the one year-overall survival
rate 72%. Patients with lung metastases had a median
OS of 26 months, compared to 14 months in patients
with multiple locations, 13 months with metastases to
the skeletal system, 21 months with liver metastases, 7
months with brain metastases and 15 months with skin
metastases. There was a significant one-year-survival dif-
ference between patients with lung metastases (82%) and
other metastatic locations (brain 0%, multiple locations
56%, liver 50% and bone 60%, p = 0.01, log rank,
figure 2). There was no difference in OS for patients
with DM from oro- or hypopharyngeal cancer (p =
0.51). The stage of nodal disease had significant influ-
ence on OS (the median OS in N0-stage was 13 months,
compared to 30 months in N2a/b-stage and 8 months in
N3-stage, p = 0.025). We did not find a significant prog-
nostic factors for the development of DM regarding
gender (p = 0.29, Fisher’s exact test), age (p = 0.85, Fish-
er’s exact test), tumor localization (p = 0.89, Fisher’s
exact test) and treatment response (p = 0.23, Fisher’s
exact test). Chronic alcohol (tobacco) abuse was not
accessible in this subgroup due to the fact that 44 (40)
of the 45 patients showed chronic alcohol (tobacco)
abuse. Local recurrence occurred in 28 patients (62%) in
addition to their DM. There was no significant differ-
ence regarding OS of patients with DM alone compared
to patients with LR and DM (1-year survival 53% and
58%, respectively).
Survival
At last follow-up, 33 patients (26%) were still alive and
94 patients (74%) had passed. The median overall (dis-
ease free) survival time was 27 months (11 months) and
the 3-, 5- and 10-year overall (disease free) survival rates
were 39% (30%), 28% (24%) and 14% (22%), respectively
(figure 3). The cause of death was tumor dependent in
69 patients (73%). In 4 patients (4%) the cause of death
was another carcinoma and in one patient each (1%)
cardiac insufficiency and pulmonary embolism. In 19
patients (20%) the cause of death was not documented.
T h eu n i v a r i a t ea n a l y s i so nt h ei n f l u e n c eo fU I C C
tumor stage on OS showed a borderline significance for
patients with stage IVA disease versus IVB (p = 0.06).
Figure 1 Overall survival of 45 patients with development of
distant metastases.
Hauswald et al. Radiation Oncology 2011, 6:70
http://www.ro-journal.com/content/6/1/70
Page 3 of 7OS in patients with N2 disease (median 29 months, 3-,
5- and 10-year-OS was 42%, 28% and 15%, respectively)
a borderline significantly longer OS compared to
patients with N3 disease (median 11 months, 3-, 5- and
10-year-OS was 29%, 22% and 11%, respectively; p =
0.06). The localization of the primary tumor, whether
hypo- or oropharyngeal, had no significant influence on
the OS (median 26 vs. 29 months, p = 0.55). One other
univariate prognostic factor was alcohol abuse (n = 102,
p = 0.015). Further more, patients with a CR had a sig-
nificantly improved OS compared to patients with a PR
(median 59 months versus 17 months, p < 0.001, figure
4). We did not find a significant influence on OS by
t o b a c c oa b u s e( p=0 . 4 4 ) ,a g e> / =5 5y e a r s( p=0 . 4 5 ) ,
median treatment dose >/= 66.4 Gy (p = 0.5) and total
radiooncological treatment time >/= 40 days (p = 0.7).
T h es a m p l eo fp a t i e n t sw h ow e r eH P 1 6 / p 1 6p o s i t i v e
was too small for useful statistical analysis. The results
of the uni- and multivariate analyses were shown in
table 2 and table 3, respectively.
Long-term side effects
Most common long-term side effects documented were
xerostomia and alterations in taste. At last follow-up, 17
of the 33 patients who were still alive (51%) reported
grade III to IV xerostomia.
Second primary carcinoma
Second primary carcinomas developed in 27 patients
(21%). Their most common location was the head and
neck region (n = 9), followed by the esophagus (n = 6),
lungs (n = 5) and stomach (n = 2). One patient each
developed a hepatocellular-, pancreatic-, penile-, pro-
static- and renal cell carcinoma. Patients with secondary
carcinomas did not have a significantly longer survival
than those without secondary tumors (46 months versus
25 months, p = 0.26).
Discussion
We report on a retrospective analysis of the treatment
results in 127 patients treated with concurrent, plati-
num-based, hyperfractionated-accelerated radioche-
motherapy between 1992 and 2005 for primarily
inoperable advanced oro-and hypopharyngeal squamous
Figure 2 Survival of patients with pulmonal (n=17) versus elsewhere located (n=28) metastases.
Figure 3 Overall survival of 127 patients with primarily
inoperable, advanced HNSCC.
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oro- and hypopharyngeal squamous cell carcinoma is a
definite concurrent platinum-based radiochemotherapy.
In the daily routine, guidelines regarding the optimal
treatment of the patients, including those with DM, are
warranted. This study’s aim was to evaluate the long-
term treatment outcome at our institution as well as
patterns of failure and help finding ways to improve
prognosis, morbidity and mortality in patients with
advanced HNSCC.
The treatment regime used in our patients was based
on the prospective and multicentre trial on radiotherapy
in advanced head and neck cancer initially published by
Staar et al [19]. After accelerated and hyperfractionated
radiotherapy with concurrent 5-FU and carboplatinum
chemotherapy the authors achieved a 1- and 2-year OS
rate of 66% and 48%, respectively. The total response to
treatment was above 90%. The rate of xerostomia 1 year
after treatment was 66%. An update on the report was
recently published by Semrau et al [20]. The reported 5-
year overall survival rate was 25.6% and the median survi-
val 23 months. In a trial on concomitant radioche-
motherapy in advanced oropharyngeal cancer Denis et al
reported an median survival of 20 months and a 5-year
overall survival rate of 22% for patients treated with con-
comitant radiochemotherapy [21]. The 3-, 5- and 10-year
OS rates of 39%, 28% and 14%, respectively as well as the
median OS of 23 months in our cohort were comparable
and in good agreement to the published data.
Adelstein et al reported on 222 patients with advanced
head and neck squamous cell carcinoma treated with a
multiagent concurrent radiochemotherapy with 5-FU
and cisplatin during weeks 1 and 4 [22]. The tumor was
located in the oropharynx in 52%. The 5-year OS rate
was 65%. This superiority of the results by Adelstein et
al may be due to the selection, since preserving organ
function was one mayor concern and patients with
tumor-invasion into the bone or cartilage were not con-
sidered appropriate for this treatment approach. In their
report on 81 patients treated with hypofractionated
Figure 4 Survival of patients with a complete remission (n=47) versus partial remission (n=78).
Table 2 Results of the univariate analyses
Factor p-value
Stage IVa versus IVb 0.06
Stage N2 versus N3 0.06
Total dose of irradiation (>/= or <66,4Gy) >0.1
Total radiooncological treatment time (>/= or <40 days) 0.7
Complete versus partial remission <0.001
Age (>/= or <55 years) >0.1
Alcohol abuse 0.015
Secondary primary tumors >0.1
Hauswald et al. Radiation Oncology 2011, 6:70
http://www.ro-journal.com/content/6/1/70
Page 5 of 7accelerated radiotherapy and concurrent chemotherapy
for advanced HNSCC (including larynx, oral cavity, oro-
and hypopharynx) Sanghera et al reported a 2-year OS
rate of 67.8% in 68 patients with UICC stage III and IV
[23]. The superiority of these results may be due to the
lower count of T4 tumors (25/81 patients) and lower
count of N2c or N3 disease (14/81 patients) in the
cohort of Sanghera et al. Improvements in survival with
1- and 2-year OS rates of up to 81.5% and 71.6% and
loco-regional tumor relapse rates of 33-35% were found
in studies on concomitant boost accelerated radiation
regimes with concomitant cisplatin [4,8].
As seen in our results as well as in earlier reports,
there is a high incidence of persistent xerostomia which
could negatively influence quality of life. An actual
approach of reducing side effects of radiation therapy
was published by Teguh et al. [24]. The authors con-
cluded that hyperbaric oxygen therapy shortly after fin-
ishing radiation therapy is an effective option for
reducing radiation-induced side effects.
In the question of factors influencing the incidence of
DM different variables as tumor stage, histological pat-
terns and loco-regional tumor control were reported.
Best predictor for overall survival and distant failure as
reported by Brockstein et al was the stage of nodal dis-
ease [25]. Leon et al analysed 1244 patients with loco-
regionally controlled head and neck cancers. They found
N-stage, T-stage and the localization of the tumor at
hypopharynx or supraglottis to be variables increasing
the incidence of DM on multivariate analysis [26]. In
the multivariate analysis of Lim et al the presence of
pathologic positive lymph node, especially bilateral neck
metastases, was an independent risk factor for the
appearance of isolated distant metastases in oral and
oropharyngeal squamous cell carcinoma [16]. In our
patient group, the stage of nodal disease was a signifi-
cant predictor for survival (p = 0.025), but neither pri-
mary tumor localization (p = 0.89), nor treatment
response (p = 0.23) or age (p = 0.85) were significantly
related to the development of distant metastases. This
finding might be due to the fact of a relatively small
cohort. Extracapsular tumor spread and histological
grading were retrospectively not accessible.
The most common site of distant metastases in pre-
viously published data as well as found in our cohort’s
findings were the lungs [9,14,27]. Furthermore, in the
report by Alvi et al. DM developed after a mean time of
15 months and survival was 5 months after diagnosis of
DM [27]. Median time to distant failure (median 8
months) and median OS (median 16 months) in our
cohort were comparable, keeping in mind that the time
estimation in our analysis started at the initial diagnosis
of the oro- or hypopharyngeal carcinoma. In general the
salvage rates for distant failure were poor. Spector et al
reported a curing rate of 16% in pyriform carcinoma
with early solitary focal DM [14]. A 5-year survival rate
of 43% after surgical resection achieved Mazer et al on
44 patients with pulmonary metastases from upper aero-
digestative tract cancer [28]. Finley et al reported on
their evaluation of surgical resection of pulmonary
metastases of head and neck cancer that a resection of a
solitary pulmonary metastasis resulted in long-term sur-
vival in selected patients [29]. Since treatment after
diagnosis of DM was palliative and individual in most
cases in our cohort, it was not useful to analyze the dif-
ferent treatment approaches in the situation of DM.
Conclusion
Hyperfractionated-accelerated radiotherapy with concur-
rent platinum-based chemotherapy is an effective treat-
ment option and offers a chance for long-term survival
for patients with primarily inoperable, advanced
HNSCC, which is still rare. New and optimized treat-
ment methods increase loco-regional tumor control in
patients with advanced head and neck carcinomas and
thereby survival. So stage IV patients might be diag-
nosed with DM and this might become a relevant pro-
blem in achieving long-term control. Patients with DM
restricted to the lungs had the most favourable prog-
nosis compared to patients with other metastatic loca-
tions. Intensified palliative treatment might be justified
especially in cases of DM limited to the lungs.
Author details
1Department of Radiation Oncology, University of Heidelberg, Heidelberg,
Germany.
2Department of Oto-Rhino-Laryngology, University of Heidelberg,
Heidelberg, Germany.
Authors’ contributions
HH: analysis and interpretation of data, writing manuscript. CS: critically
revision for important intellectual content, interpretation of data. Simone
Hecht: acquisition and analysis of data. JD: critically revision for important
intellectual content, interpretation of data. KL: substantial contributions to
conception and design; critically revision for important intellectual content;
final approval for publication. All authors have read and approved the final
manuscript.
Table 3 Results of the multivariate analyses on LPFS, DFS
and OS
Factor p-value LPFS p-value DFS p-value OS
Stage IVa versus IVb >0.1 >0.1 0.16
Stage N2 versus N3 0.045 >0.1 >0.1
CR versus PR <0.001 <0.001 <0.001
Distant metastases >0.1 – 0.01
Loco-regional recurrence –– 0.006
Age (>/= or <55 years) 0.041 0.003 >0.1
Alcohol abuse >0.1 0.027 >0.1
Hauswald et al. Radiation Oncology 2011, 6:70
http://www.ro-journal.com/content/6/1/70
Page 6 of 7Competing interests
The authors declare that they have no competing interests.
Received: 19 January 2011 Accepted: 10 June 2011
Published: 10 June 2011
References
1. Batzler W, Giersiepen K, Hentschel S: Krebs in Deutschland 2003 - 2004.
Häufigkeiten und Trends. 2008 [http://www.rki.de/cln_151/nn_205770/DE/
Content/GBE/Gesundheitsberichterstattung/GBEDownloadsB/KID2008,
templateId = raw,property = publicationFile.pdf/KID2008.pdf].
2. Mashberg A, Boffetta P, Winkelman R, Garfinkel L: Tobacco smoking,
alcohol drinking, and cancer of the oral cavity and oropharynx among
U.S. veterans. Cancer 1993, 72:1369-1375.
3. Lagiou P, Georgila C, Minaki P, Ahrens W, Pohlabeln H, Benhamou S,
Bouchardy C, Slamova A, Schejbalova M, Merletti F, Richiardi L, Kjaerheim K,
Agudo A, Castellsague X, Macfarlane TV, Macfarlane GJ, Talamini R, Barzan L,
Canova C, Simonato L, Lowry R, Conway DI, McKinney PA, Znaor A,
McCartan BE, Healy C, Nelis M, Metspalu A, Marron M, Hashibe M,
Brennan PJ: Alcohol-related cancers and genetic susceptibility in Europe:
the ARCAGE project: study samples and data collection. Eur J Cancer Prev
2009, 18:76-84.
4. Ang KK, Harris J, Garden AS, Trotti A, Jones CU, Carrascosa L, Cheng JD,
Spencer SS, Forastiere A, Weber RS: Concomitant boost radiation plus
concurrent cisplatin for advanced head and neck carcinomas: radiation
therapy oncology group phase II trial 99-14. J Clin Oncol 2005,
23:3008-3015.
5. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC,
Le Maître A, Pajak TF, Poulsen MG, O’Sullivan B, Dobrowsky W, Hliniak A,
Skladowski K, Hay JH, Pinto LHJ, Fallai C, Fu KK, Sylvester R, Pignon JP:
Hyperfractionated or accelerated radiotherapy in head and neck cancer:
a meta-analysis. Lancet 2006, 368:843-854.
6. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH,
Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A,
van Glabbeke M: Postoperative irradiation with or without concomitant
chemotherapy for locally advanced head and neck cancer. N Engl J Med
2004, 350:1945-1952.
7. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU,
Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H,
Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for
squamous-cell carcinoma of the head and neck. N Engl J Med 2006,
354:567-578.
8. Garden AS, Harris J, Trotti A, Jones CU, Carrascosa L, Cheng JD, Spencer SS,
Forastiere A, Weber RS, Ang KK: Long-term results of concomitant boost
radiation plus concurrent cisplatin for advanced head and neck
carcinomas: a phase II trial of the radiation therapy oncology group
(RTOG 99-14). Int J Radiat Oncol Biol Phys 2008, 71:1351-1355.
9. Garavello W, Ciardo A, Spreafico R, Gaini RM: Risk factors for distant
metastases in head and neck squamous cell carcinoma. Arch Otolaryngol
Head Neck Surg 2006, 132:762-766.
10. Jäckel MC, Reischl A, Huppert P: Efficacy of radiologic screening for
distant metastases and second primaries in newly diagnosed patients
with head and neck cancer. Laryngoscope 2007, 117:242-247.
11. Dietl B, Marienhagen J, Schaefer C, Pohl F, Kölbl O: [Frequency and
distribution pattern of distant metastases in patients with ENT tumors
and their consequences for pretherapeutic staging]. Strahlenther Onkol
2007, 183:138-143.
12. Senft A, de Bree R, Hoekstra OS, Kuik DJ, Golding RP, Oyen WJG, Pruim J,
van den Hoogen FJ, Roodenburg JLN, Leemans CR: Screening for distant
metastases in head and neck cancer patients by chest CT or whole
body FDG-PET: a prospective multicenter trial. Radiother Oncol 2008,
87:221-229.
13. Merino OR, Lindberg RD, Fletcher GH: An analysis of distant metastases
from squamous cell carcinoma of the upper respiratory and digestive
tracts. Cancer 1977, 40:145-151.
14. Spector JG, Sessions DG, Haughey BH, Chao KS, Simpson J, El Mofty S,
Perez CA: Delayed regional metastases, distant metastases, and second
primary malignancies in squamous cell carcinomas of the larynx and
hypopharynx. Laryngoscope 2001, 111:1079-1087.
15. Kotwall C, Sako K, Razack MS, Rao U, Bakamjian V, Shedd DP: Metastatic
patterns in squamous cell cancer of the head and neck. Am J Surg 1987,
154:439-442.
16. Lim YC, Koo BS, Choi EC: Bilateral neck node metastasis: a predictor of
isolated distant metastasis in patients with oral and oropharyngeal
squamous cell carcinoma after primary curative surgery. Laryngoscope
2007, 117:1576-1580.
17. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, Forastiere A,
Gillison ML: Improved survival of patients with human papillomavirus-
positive head and neck squamous cell carcinoma in a prospective
clinical trial. J Natl Cancer Inst 2008, 100:261-269.
18. Loh KS, Brown DH, Baker JT, Gilbert RW, Gullane PJ, Irish JC: A rational
approach to pulmonary screening in newly diagnosed head and neck
cancer. Head Neck 2005, 27:990-994.
19. Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, Flentje M,
Eckel HE, Mueller RP: Intensified hyperfractionated accelerated
radiotherapy limits the additional benefit of simultaneous
chemotherapy–results of a multicentric randomized German trial in
advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001,
50:1161-1171.
20. Semrau R, Mueller RP, Stuetzer H, Staar S, Schroeder U, Guntinas-Lichius O,
Kocher M, Eich HT, Dietz A, Flentje M, Rudat V, Volling P, Schroeder M,
Eckel HE: Efficacy of intensified hyperfractionated and accelerated
radiotherapy and concurrent chemotherapy with carboplatin and 5-
fluorouracil: updated results of a randomized multicentric trial in
advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006,
64:1308-1316.
21. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P,
Rhein B, Tortochaux J, Calais G: Final results of the 94-01 French Head
and Neck Oncology and Radiotherapy Group randomized trial
comparing radiotherapy alone with concomitant radiochemotherapy in
advanced-stage oropharynx carcinoma. J Clin Oncol 2004, 22:69-76.
22. Adelstein DJ, Saxton JP, Rybicki LA, Esclamado RM, Wood BG, Strome M,
Lavertu P, Lorenz RR, Carroll MA: Multiagent concurrent
chemoradiotherapy for locoregionally advanced squamous cell head
and neck cancer: mature results from a single institution. J Clin Oncol
2006, 24:1064-1071.
23. Sanghera P, McConkey C, Ho KF, Glaholm J, Hartley A: Hypofractionated
accelerated radiotherapy with concurrent chemotherapy for locally
advanced squamous cell carcinoma of the head and neck. Int J Radiat
Oncol Biol Phys 2007, 67:1342-1351.
24. Teguh DN, Levendag PC, Noever I, Voet P, van der Est H, van Rooij P,
Dumans AG, de Boer MF, van der Huls MPC, Sterk W, Schmitz PIM: Early
hyperbaric oxygen therapy for reducing radiotherapy side effects: early
results of a randomized trial in oropharyngeal and nasopharyngeal
cancer. Int J Radiat Oncol Biol Phys 2009, 75:711-716.
25. Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, Rosen F,
Mittal BB, Pelzer H, Fung BB, Witt ME, Wenig B, Portugal L,
Weichselbaum RW, Vokes EE: Patterns of failure, prognostic factors and
survival in locoregionally advanced head and neck cancer treated with
concomitant chemoradiotherapy: a 9-year, 337-patient, multi-
institutional experience. Ann Oncol 2004, 15:1179-1186.
26. León X, Quer M, Orús C, del Prado Venegas M, López M: Distant
metastases in head and neck cancer patients who achieved loco-
regional control. Head Neck 2000, 22:680-686.
27. Alvi A, Johnson JT: Development of distant metastasis after treatment of
advanced-stage head and neck cancer. Head Neck 1997, 19:500-505.
28. Mazer TM, Robbins KT, McMurtrey MJ, Byers RM: Resection of pulmonary
metastases from squamous carcinoma of the head and neck. Am J Surg
1988, 156:238-242.
29. Finley RK, Verazin GT, Driscoll DL, Blumenson LE, Takita H, Bakamjian V,
Sako K, Hicks W, Petrelli NJ, Shedd DP: Results of surgical resection of
pulmonary metastases of squamous cell carcinoma of the head and
neck. Am J Surg 1992, 164:594-598.
doi:10.1186/1748-717X-6-70
Cite this article as: Hauswald et al.: Long-term outcome and patterns of
failure in patients with advanced head and neck cancer. Radiation
Oncology 2011 6:70.
Hauswald et al. Radiation Oncology 2011, 6:70
http://www.ro-journal.com/content/6/1/70
Page 7 of 7